ClinicalTrials.gg
Not yet recruitingNCT06851078KiSSUpdated Mar 12, 2025

Evaluation of Early Administration of Levetiracetam in the Prevention and Treatment Encephalopathy in Septic Shock: Randomized, Double-blind, Placebo-controlled Trial

A Phase 3 interventional study of Levetiracetam IV and Placebo control in Septic Shock, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris — 15 open to participants now, 16 under way, 3 of them phase 3. Shock, Septic · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
6th of 17
280 · median 210
Started
2025
the only one that year
Phase 3
8 of 30
3 open now
Primary completion
2027-06
later than 9 of 15 live
Registered
23rd of 30
by date

Among the 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2025, is one of 8 in phase 3, reaches primary completion later than 9 of the 15 other live ones, and was the 23rd registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

15 of the 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Sepsis-associated encephalopathy is associated with high mortality rates and long-term neuropsychiatric disorders. Currently, there is no specific treatment for sepsis-associated encephalopathy. Levetiracetam, a broad-spectrum antiepileptic widely used in intensive care units, has neuroprotective properties. We propose the KiSS study, a multicenter, prospective, randomized, double-blind trial with two arms, evaluating the effect of levetiracetam treatment for seven days during septic shock on the occurrence and duration of sepsis-associated encephalopathy.

03

Conditions studied

  • Septic Shock

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria :

  • Aged 18 years or older
  • Hospitalized in intensive care for less than 96 hours
  • Presenting with septic shock evolving for less than 24 hours defined by:

    1. Clinically or microbiologically documented infection and
    2. SOFA score ≥ 2 or an increase in SOFA score ≥ 2 points if organ dysfunction was present before the infection and
    3. Need for vasopressor administration to maintain a mean arterial pressure ≥ 65mmHg and
    4. Lactate level > 2mmol/L (18mg/dL) despite adequate fluid resuscitation
  • Patient's consent, their next of kin consent, or emergency inclusion

Non inclusion criteria :

  • Chronic long-term antiepileptic treatment upon admission or patient with uncontrolled seizures
  • Chronic or progressive central neurological pathologies of traumatic, inflammatory, vascular, infectious, neoplastic, or degenerative origin, defined by cognitive impairments preventing independent living or an IQCODE score > 4.5
  • Patient with moderate to severe dementia
  • Patient with psychiatric history and/or suicide attempts
  • Severe head trauma within the past 3 months
  • Patients with limitations on active therapies or for whom therapeutic commitment is not maximal
  • Patient presenting a prolonged on and/or at risk of cardiovascular disease
  • Concomitant treatment with Methotrexate during the administration of the treatment
  • Allergy to levetiracetam
  • Minor patients
  • Ongoing pregnancy (blood or urinary βHCG)
  • Breastfeeding women
  • Patients under guardianship or trusteeship
  • Non-affiliation with social security or CMU
  • Participation in another interventional trial with a drug that may interact with levetiracetam or may impact the evaluation of KiSS trial outcomes. In case of doubt, please contact the trial's coordinating investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Early Levetiracetam administration

    Drug: Levetiracetam IV

  • Placebo comparator
    Placebo control

    Other: Placebo control

Interventions

  • DrugLevetiracetamStudies of LevetiracetamLevetiracetam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1000 mg twice a day during 7 days maximum

  • OtherPlacebo control

    NaCl 0.9% sodium chloride in the same route and method of administration as experimental treatment

06

What researchers measure

Primary outcomes

  1. Number of days alive without delirium or coma

    Time frame: 14 days after randomization

Secondary outcomes

  1. Mortality in intensive care

    Time frame: At day 28

  2. Mortality in intensive care

    Time frame: At day 90

  3. Mortality in hospital

    Time frame: At day 28

  4. Mortality in hospital

    Time frame: At day 90

  5. Overall survival

    Time frame: At day 90

  6. Duration of mechanical ventilation

    Time frame: At day 28

  7. Length of stay in intensive care unit

    Time frame: Up to day 90

  8. Length of stay in hospital

    Time frame: Up to day 90

  9. Occurrence of epileptic seizures

    From Day 1 to Day 14 (confirmed by EEG or tonic-clonic seizures) and/or occurrence of epileptic abnormalities (periodic epileptic discharges)

    Time frame: Up to day 14

  10. Time between cessation of sedation and awakening

    Defined by spontaneous eye opening, among patients not deceased under sedation

    Time frame: At day 90

  11. Severity of cognitive impairment

    Evaluated by a telephone survey using Telephone MoCA (Montreal Cognitive Assessment). The scores ranges from 0 to 30. A score of 26 or higher is typically considered normal. A score of 25 or lower may indicate cognitive impairment, such as mild cognitive impairment (MCI) or early-stage dementia.

    Time frame: At day 90

  12. Severity of anxiety and depression

    Assessed with HADS (Hospital Anxiety and Depression Scale) scale Score varies from 0 to 21 for each componant (Anxiety and depression) The higher the score, the more severe the anxiety or depression.

    Time frame: At day 90

  13. Presence of post-traumatic stress (PTSD)

    Assessed by IES-R (Impact of Event Scale Revisited) The total score can range from 0 to 88. Higher scores indicate greater trauma-related distress and a higher likelihood of experiencing PTSD symptoms.

    Time frame: At day 90

  14. Quality of life scoring

    Using EQ-5D-5L. It evaluates five dimensions : mobility, self-care, usual activities, pain/discomfort and anxiety/depression and each dimension has five levels : no problems, slight problems, moderate problems, severe problems and extreme problems. Answers are given on a 5-point scale by domain, the higher the score, the poorer the quality of life.

    Time frame: At day 90

  15. Autonomy in daily life

    Using Katz Index of Independence in Activities of Daily Living (ADL) The score varies from 0 to 6, the lower the score, the more dependent the person.

    Time frame: At day 90

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Jun 2027, 27 months later.

Of 45 non-industry phase 3 interventional studies under Shock, Septic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 59. This study's planned 27 months is below that.

Counting every sponsor, half of 46 studies reached it within 42 months; a quarter within 16 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Feb 28, 2025
StartEst.
Mar 15, 2025
Primary completionEst.
Jun 15, 2027
CompletionEst.
Jun 15, 2027
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06851078
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
Mar 15, 2025 (estimated)
Primary completion
Jun 15, 2027 (estimated)
Completion
Jun 15, 2027 (estimated)
Last update
Mar 12, 2025

Study contacts

Shidasp Siami, MD
Contact
shidasp.siami@ch-sudessonne.fr
160807940 ext. +33
Jérôme Lambert, MD PhD
Contact
jerome.lambert@u-paris.fr
0142499742 ext. +33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion